Expertise in
6
conditions

Pei-jer H. Chen

7 Chung Shan South Road, 
TPQ, TW 
Expertise in
6
conditions
7 Chung Shan South Road, 
TPQ, TW 

Overview

Pei-jer Chen practices practicing medicine in Taiwan.

Chen is highly rated in 6 conditions, according to our data. Their clinical expertise encompasses Hepatitis, Hepatitis B, Hepatitis C, Liver Cancer, and Liver Embolization.

They are actively involved in clinical research, co-authoring 464 peer reviewed articles and participating in 4 clinical trials.

Locations

7 Chung Shan South Road, TPQ 10002, Taiwan
Other Locations
No.1, Changde Street, Zhongzheng District, TPQ 10048, Taiwan
No. 1, Jen Ai Road, TPQ 10051, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Enrollment Status: Completed
Publish Date: March 11, 2020
Intervention Type: Drug
Study Phase: Phase 4
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Enrollment Status: Completed
Publish Date: October 15, 2019
Intervention Type: Biological, Drug
Study Phase: Phase 1
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Enrollment Status: Completed
Publish Date: July 19, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

464 Total Publications

Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis.
Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 18, 2026

Frequently Asked Questions about Pei-jer H. Chen

Is Pei-jer H. Chen a top-rated expert for Hepatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Pei-jer H. Chen is classified as an Distinguished expert for Hepatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Pei-jer H. Chen participate in research or clinical trials?

Yes. Pei-jer H. Chen has published 464 articles and abstracts on conditions like Hepatitis. You can view a list of Pei-jer H. Chen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chen's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile